Pfizer (PFE)
(Delayed Data from NYSE)
$28.30 USD
-0.41 (-1.43%)
Updated Aug 16, 2024 04:01 PM ET
After-Market: $28.27 -0.03 (-0.11%) 5:52 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.30 USD
-0.41 (-1.43%)
Updated Aug 16, 2024 04:01 PM ET
After-Market: $28.27 -0.03 (-0.11%) 5:52 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Quality Dividend ETFs for Turbulent Times
by Zacks Equity Research
Consider these 3 dividend ETFs for your portfolio to fight rising market uncertainty.
Agilent Boosts Market Share With FDA Nod to New Cancer Test
by Zacks Equity Research
Agilent Technologies' (A) recent FDA approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx for UC and SCCHN patients will further expand its share in the growing cancer-diagnostic market.
Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs
by Arpita Dutt
Industry heavyweights like Johnson & Johnson (JNJ), Merck and Bristol-Myers were in the news related to regulatory updates.
Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda received FDA approval for advanced gastric cancer, making it the tenth new indication approved for Keytruda.
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
by Zacks Equity Research
Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.
Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com
by Swarup Gupta
The Dow mopped up gains over the week, buoyed by announcements from the Federal Reserve.
Cancer Space Update: Mixed Week for Pfizer, Roche Falters
by Zacks Equity Research
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update
by Arpita Dutt
Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake
by Zacks Equity Research
Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.
Can Pfizer (PFE) Prove to be an Apt Value Investment?
by Zacks Equity Research
Let's find out if Pfizer, Inc. (PFE) stock is a good choice for value-oriented investors right now
Mylan Down 24% Year to Date: What's Troubling the Stock?
by Zacks Equity Research
Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.
Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View
by Zacks Equity Research
Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
: Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.
Neos Therapeutics ADHD Drug Adzenys Receives Approval in US
by Zacks Equity Research
Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.
Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.
Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO
by Arpita Dutt
Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.
Why Did Pfizer (PFE) Stock Pop Today?
by Ryan McQueeney
Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.
The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk
Top Analyst Reports for Apple, Pfizer & Carnival
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Pfizer (PFE) and Carnival (CCL).
Bristol-Myers Reports Positive Results from Melanoma Study
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo.
AbbVie's RA Candidate Meets Primary Endpoint in Phase III
by Zacks Equity Research
AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.
Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable
by Zacks Equity Research
Pfizer (PFE) announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).
3 Excellent Dividend ETFs for Turbulent Times
by Zacks Equity Research
Consider these 3 Dividend ETFs for your portfolio to battle market uncertainty.
Bristol-Myers' Opdivo Study Meets Early Success, Stock Up
by Zacks Equity Research
Bristol-Myers' (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.
Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval
by Swarup Gupta
The Dow endured significant losses over a holiday-shortened trading week.